ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC) Options
In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Individuals will acquire treatment till sickness progression or even the members are unable to tolerate the study drugs.Achievable new methods for the analysis and treatment of AML. (A) The identification of Tremendous e